Zika Virus Testing Industry Navigating the Growth Trajectory Towards a US$ 6.8 Million Milestone by 2033-FMI Report

The zika virus testing industry stands as a crucial bulwark in the defense against a formidable global health threat. Zika virus, transmitted primarily through mosquito bites, gained widespread attention due to its potential to cause serious birth defects and neurological complications. Testing for Zika virus infection is paramount for identifying cases, implementing timely interventions, and preventing its spread. The market for Zika virus testing has emerged as a critical component of public health strategies, playing a pivotal role in safeguarding vulnerable populations and preventing outbreaks.

Early and accurate detection of the Zika virus is of paramount importance, especially for pregnant individuals and those planning to conceive. Zika virus infection during pregnancy has been linked to microcephaly and other birth defects in newborns. Timely testing enables healthcare professionals to counsel and provide appropriate care, helping expectant mothers make informed decisions to protect themselves and their babies.

Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-2913

According to FMI, the global Zika virus testing market will grow from US$ 4.9 million in 2023 to US$ 6.8 million by 2033. The market is expected to grow at a CAGR of 3.4% during the forecast period. The rising incidence of Zika virus infection is the primary driver of the rising consumption of Zika virus testing over the forecast period.

The global zika virus testing market experienced a moderate incline, experiencing a CAGR of just above 2% between 2017 and 2020, being valued at a little over US$ 4 billion, as per ESOMAR-certified firm Future Market Insights (FMI) latest report on the landscape.

Growth was majorly underpinned by the introduction of numerous point-of-care powerful testing approaches to facilitate timely detection of the virus. According to FMI’s analysis, clinicians have been exhibiting a high preference towards enzyme linked immunosorbent assay (ELISA) tests.

Compared to other immunoassay methods, ELISA tests are more accurate, are considered highly sensitive, specific and compare favorably with other methods used to detect substances in the body, such as radioimmune assay (RIA) tests.

Prominent players are experiencing immense growth opportunities across tropical regions, attributed to the high concentration rate of the zika virus across such regions as the Caribbean, Central America, Africa and the Asian sub-continent.

Players such as EUROIMMUN have emerged at the forefront, being the first diagnostics company to provide a testing approach to detect the zika virus. Its product lines include the Anti-Zika Virus ELISA (IgA or IgG or IgM or IgAM) fully automatable test and the IIFT Arbovirus Fever Mosaic 2 (IgG or IgM) test.

Key Takeaways :

• By test type, ELISA-based zika virus testing surpassed US$ 4 billion until 2020
• By end-user, private commercial laboratories to remain primary point of contact for availing zika virus testing
• Multiple regulatory approvals for various testing approaches by the FDA to bolster US zika virus testing market growth
• Brazil to attract major zika virus testing providers amid increasing governmental initiatives to contain its spread
• Growing focus on pregnant women’s health to accelerate testing volumes in Puerto Rico
• UK to experience limited uptake amid the non-notifiable nature of the disease due to limited outbreaks

Unlock Tailored Insights: Customize Your Report for Maximum Impact :
https://www.futuremarketinsights.com/customization-available/rep-gb-2913

Competitive Landscape :

Prominent zika virus testing manufacturers are reliant on offering advanced testing approaches in order to yield quicker results so as to facilitate timely treatment.

Besides, key research laboratories and organizations also emphasize on expanding their testing capabilities by virtue of strategic acquisition and collaboration agreements.

In 2017, the US FDA issued an Emergency Use Authorization (EUA) to authorize the RealStar^® Zika Virus RT-PCR Kit for the in vitro qualitative detection of Zika virus with specified instruments.

This test is offered by Altona Diagnostics GmbH, and tests presence of the virus in human serum, EDTA plasma and/or urine. Similarly, ARUP Laboratories offers both serology and RT-PCR tests for detecting the zika virus. The former is called the Zika Virus IgM Antibody Capture (MAC) based on the ELISA technique. In the latter case, the test is conducted by collecting patients’ blood or urine samples.

Key Segments Covered :

Test Type

• Rapid IgG/IgM Test
• ELISA Test

End-User

• Hospitals & Clinics
• Private Commercial Laboratories
• Government/Publicly Funded Programs

Region:

• North America & Europe (US, UK, Germany, Spain, France, Italy and Rest of Europe)
• Latin America (Brazil, Mexico, Colombia and Rest of LATAM)
• Central America (Costa Rica, Nicaragua, Guatemala and Rest of Central America)
• Caribbean (Puerto Rico and Rest of the Caribbean)
• South East Asia (Thailand, Singapore, Vietnam and Rest of South East Asia)
• Rest of the World (North Africa and South Africa)

Unlock exclusive insights with our expert analysts :
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2913

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube